SS-31 study limits: a PH guide to “Efficacy and Safety of Elamipretide in…”

Quick answer

For “Efficacy and Safety of Elamipretide in…,” the MMPOWER-3 phase 3 trial in 218 adults with primary mitochondrial myopathy did not meet its primary endpoints for improving the six-minute walk distance or total fatigue score after 24 weeks.¹

In the “Efficacy and Safety of Elamipretide in…” source, this was the overall result for a genetically diverse population¹ For Filipino readers, the practical move is to keep that finding attached to the cited study and verify any local product claim as a separate question.

Start with the study question

This article starts from “Efficacy and Safety of Elamipretide in…” because its result is more useful than a loose promise about SS-31.

The paper becomes easier to read once the measured outcome is named first. In “Efficacy and Safety of Elamipretide in…,” the MMPOWER-3 phase 3 trial in 218 adults with primary mitochondrial myopathy did not meet its primary endpoints for improving the six-minute walk distance or total fatigue score after 24 weeks.¹

The MMPOWER-3 randomized, placebo-controlled trial reported that the study did not meet its primary efficacy endpoints for change in 6MWT or PMMSA total fatigue score at week 24.¹ For “Efficacy and Safety of Elamipretide in…,” the design matters because a laboratory signal, an animal model, an observational record, and a randomized trial carry different kinds of certainty.¹

This was the overall result for a genetically diverse population.¹ In this “Efficacy and Safety of Elamipretide in…” reading, uncertainty is part of the result, not a footnote to remove when the article becomes shorter.¹

Readers researching SS-31 after reading “Efficacy and Safety of Elamipretide in…” can view its live catalog details below. The listing identifies the catalog item and remains separate from this source-specific evidence discussion.

What the central result actually says

The wider SS-31 record in “Efficacy and Safety of Elamipretide in…” matters only when each result keeps its original population and outcome.

A precise result is more useful here than a dramatic yes-or-no verdict. In “Efficacy and Safety of Elamipretide in…,” SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin.²

The FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder.² A laboratory study notes SS-31's known property of mitochondrial inner membrane binding.² That distinction helps keep the broader discussion within clear limits.

This is a description of its mechanism of action from regulatory and laboratory sources.² In this “Efficacy and Safety of Elamipretide in…” reading, a careful limit makes the finding more trustworthy because another reader can retrace the reasoning.²

Why the design changes the meaning

For “Efficacy and Safety of Elamipretide in…,” evidence categories answer different questions, so this section keeps methods visible beside the findings.

The first task is to restore the study details that a headline tends to remove. In “Efficacy and Safety of Elamipretide in…,” in a 12-week randomized trial of 12 males with Barth syndrome, the primary endpoints included the distance walked in six minutes and a measure of muscle strength.³

The FDA snapshot describes the randomized portion of SPIBA-201 in patients aged 12 years or older and weighing more than 30 kg.³ For “Efficacy and Safety of Elamipretide in…,” the comparator, endpoint, timeframe, and study population should travel with the finding whenever it is summarized.³

Knee-extensor muscle strength was a secondary endpoint, not a primary endpoint.³ In this “Efficacy and Safety of Elamipretide in…” reading, the study may inform the next question without settling every clinical, commercial, or personal question.³

Where the conclusion must stop

In “Efficacy and Safety of Elamipretide in…,” limits are doing real work: they prevent a narrow result from becoming a general recommendation.

Research identity and product identity are different

For “Efficacy and Safety of Elamipretide in…,” a catalog name can help locate an item, but it cannot transfer a paper’s outcome to that item.

The useful reading begins with the source, then keeps the conclusion the same size. In “Efficacy and Safety of Elamipretide in…,” the Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.⁴

Official Philippine regulatory verification service.⁴ For “Efficacy and Safety of Elamipretide in…,” reading the method beside the result is the quickest way to separate evidence from inference.⁴

A portal record applies to the exact product or establishment named in that record.⁴ In this “Efficacy and Safety of Elamipretide in…” reading, this is where responsible interpretation stops: at the edge of the measured setting.⁴

Readers comparing the “Efficacy and Safety of Elamipretide in…” question with MOTS-c can view its live catalog details below. It is a separate catalog reference, not a suggested combination.

A Philippine reading checklist

The Philippine reading of “Efficacy and Safety of Elamipretide in…” keeps global research and local verification as two separate checks.

Start with the recorded finding, not the version compressed for a feed. In “Efficacy and Safety of Elamipretide in…,” a study record is most useful when its reported result remains attached to the population, design, source identifier, and exact product identity.⁵

Editorial synthesis of the canonical research records and Philippine verification sources.⁵ For “Efficacy and Safety of Elamipretide in…,” population and method are not background trivia; they determine which question the result answers.⁵

This synthesis is educational and is not personal medical advice or a product recommendation.⁵ In this “Efficacy and Safety of Elamipretide in…” reading, that boundary does not dismiss the research. It explains the exact job this source can do.⁵

Bottom line

The sound reading of “Efficacy and Safety of Elamipretide in…” is source-sized: the MMPOWER-3 phase 3 trial in 218 adults with primary mitochondrial myopathy did not meet its primary endpoints for improving the six-minute….¹

For “Efficacy and Safety of Elamipretide in…,” This was the overall result for a genetically diverse population.¹ A portal record applies to the exact product or establishment named in that record.⁴

For Filipino readers, this “Efficacy and Safety of Elamipretide in…” guide is educational context. Keep the study, product identity, and Philippine verification separate; it is not medical advice.

Frequently asked questions

What is the shortest fair answer about SS-31?

For “Efficacy and Safety of Elamipretide in…,” The MMPOWER-3 phase 3 trial in 218 adults with primary mitochondrial myopathy did not meet its primary endpoints for improving the six-minute walk distance or total fatigue score after 24 weeks.¹ This was the overall result for a genetically diverse population.¹

Does one positive result settle the topic?

No. For “Efficacy and Safety of Elamipretide in…,” the FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder.² A laboratory study notes SS-31's known property of mitochondrial inner membrane binding.² This is a description of its mechanism of action from regulatory and laboratory sources.² A useful finding can remain narrow without being dismissed or promoted as a universal benefit.

Why does the study design matter?

The FDA snapshot describes the randomized portion of SPIBA-201 in patients aged 12 years or older and weighing more than 30 kg.³ For “Efficacy and Safety of Elamipretide in…,” a different population, comparator, formulation, endpoint, or timeframe would answer a different question.

What should Filipino readers verify?

The Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.⁴ For this “Efficacy and Safety of Elamipretide in…” question, check the exact product and establishment records in the separate Philippine FDA portal categories.⁴

Do the SS-31 and MOTS-c cards prove a benefit?

No. In the “Efficacy and Safety of Elamipretide in…” guide, the SS-31 and MOTS-c cards are navigation references. They do not prove study equivalence, turn research into a product claim, or suggest using the items together.⁵

Sources

Footnotes

1. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.. The MMPOWER-3 randomized, placebo-controlled trial reported that the study did not meet its primary efficacy endpoints for change in 6MWT or PMMSA total fatigue score at week 24. This was the overall result for a genetically diverse population. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹

2. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.. The FDA label describes FORZINITY (elamipretide) as a mitochondrial cardiolipin binder. A laboratory study notes SS-31's known property of mitochondrial inner membrane binding. This is a description of its mechanism of action from regulatory and laboratory sources. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

3. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE). The FDA snapshot describes the randomized portion of SPIBA-201 in patients aged 12 years or older and weighing more than 30 kg. Knee-extensor muscle strength was a secondary endpoint, not a primary endpoint. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

4. Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Official Philippine regulatory verification service. A portal record applies to the exact product or establishment named in that record. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

5. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.; Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.; Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Editorial synthesis of the canonical research records and Philippine verification sources. This synthesis is educational and is not personal medical advice or a product recommendation. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶